Tocilizumab for Severe COVID-19 Pneumonia: Experience from 5 Geriatric Chinese Patients with 6 Months Follow-up.

Liu, Aihua; Chen, Zhe; Cheng, Yongjing; Wang, Xutao; Gao, Ming; Huang, Cibo

Liu, Aihua; Chen, Zhe; Cheng, Yongjing; Wang, Xutao; Gao, Ming; Huang, Cibo.

Afiliación

Liu A; Department of Rheumatology and Immunology, Beijing Hospital, National Centre of Gerontology, Beijing, China.
Chen Z; Department of Rheumatology and Immunology, Beijing Hospital, National Centre of Gerontology, Beijing, China.
Cheng Y; Department of Rheumatology and Immunology, Beijing Hospital, National Centre of Gerontology, Beijing, China.
Wang X; Department of Emergency, Beijing Hospital, National Centre of Gerontology, Beijing, China.
Gao M; Department of Rheumatology and Immunology, Beijing Hospital, National Centre of Gerontology, Beijing, China.
Huang C; Department of Rheumatology and Immunology, Beijing Hospital, National Centre of Gerontology, Beijing, China.

Rheumatol Immunol Res ; 2(1): 35-42, 2021 Mar.

Article en En | MEDLINE | ID: mdl-36467896

Palabras clave

Tocilizumab; coronavirus disease 2019; follow-up; interleukin-6; virus shedding periods

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Rheumatol Immunol Res Año: 2021 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google